炎症性肠病成人对流感疫苗和肺炎球菌疫苗的免疫应答:1429例患者的系统评价与Meta分析
该系统评价与Meta分析纳入12项研究共1429例炎症性肠病(IBD)患者,评估流感疫苗和肺炎球菌疫苗的血清保护率和血清转化率。接受传统免疫抑制治疗的患者疫苗应答未见显著降低,但抗TNF单药或联合治疗者肺炎球菌疫苗血清转化率显著降低。作者认为,尽管存在免疫抑制,针对肺炎球菌和流感的免疫接种是安全且有免疫原性的。
要点
- 传统免疫抑制治疗者流感疫苗血清保护率和肺炎球菌疫苗血清转化率未见显著降低。
- 抗TNF单药或联合治疗者肺炎球菌疫苗血清转化率显著降低(OR分别为0.28和0.27)。
- 接受抗TNF单药或联合治疗者流感疫苗血清保护率与接受传统免疫抑制单药治疗者无显著差异。
核心结论
- 作者认为,尽管存在免疫抑制,针对肺炎球菌和流感的免疫接种是安全且有免疫原性的。
研究设计与样本
- 系统评价与Meta分析,检索4个数据库至2020年10月20日,纳入12项研究共1429例IBD患者。
主要发现
- 接受传统免疫抑制治疗者肺炎球菌疫苗血清转化率和流感疫苗血清保护率与未免疫抑制者相比未显著降低。
- 抗TNF单药治疗者肺炎球菌疫苗血清转化率显著降低(OR=0.28,95%CI 0.15-0.53)。
- 抗TNF联合治疗者肺炎球菌疫苗血清转化率显著降低(OR=0.27,95%CI 0.15-0.49)。
- 抗TNF单药治疗者流感疫苗血清保护率与接受传统免疫抑制单药治疗者无显著差异(OR=1.45,95%CI 0.62-3.38)。
- 抗TNF联合治疗者流感疫苗血清保护率与接受传统免疫抑制单药治疗者无显著差异(OR=0.91,95%CI 0.37-2.22)。
关键数值与推荐
- 肺炎球菌疫苗血清转化率:抗TNF单药治疗者OR=0.28(95%CI 0.15-0.53),抗TNF联合治疗者OR=0.27(95%CI 0.15-0.49)。
- 流感疫苗血清保护率:抗TNF单药治疗者对比传统免疫抑制单药治疗者OR=1.45(95%CI 0.62-3.38),抗TNF联合治疗者对比传统免疫抑制单药治疗者OR=0.91(95%CI 0.37-2.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with inflammatory bowel disease (IBD) have a high risk for infection. Pneumonia related to influenza and pneumococcal infection is one of the most common infection-related complications in IBD. AIMS: To evaluate the immunogenicity of pneumococcal and influenza vaccination in patients with IBD receiving different treatments. METHODS: We searched four databases for studies evaluating seroprotection and seroconversion rates after influenza or pneumococcal vaccination in IBD on 20th October 2020. In the meta-analysis, odds ratios (OR) were calculated with 95% confidence intervals (CI). RESULTS: We included twelve studies (1429 patients with IBD) in this meta-analysis. The seroconversion rate after pneumococcal vaccination and the seroprotection rate after influenza vaccination were not significantly lower in patients receiving conventional immunosuppressive treatment compared to the non-immunosuppressed patients. Meanwhile, the seroconversion rate following pneumococcal vaccine was significantly lower in patients with anti-TNF mono- or combination therapy (OR = 0.28, CI: 0.15-0.53, and OR = 0.27, CI: 0.15-0.49, respectively). In the analysis of patients with IBD on conventional immunosuppressive monotherapy versus anti-TNF therapy, the seroprotection rate after influenza immunization did not differ between patients receiving either anti-TNF mono-or combination therapy (OR = 1.45, CI: 0.62-3.38 and OR = 0.91, CI: 0.37-2.22, respectively). CONCLUSION: Our data suggest that the immunization against Pneumococcus and influenza is safe and immunogenic despite immunosuppression.
引用
- Müller KE, Dohos D, Sipos Z, et al. Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients. Vaccine. 2022. PMID: 35227523. doi:10.1016/j.vaccine.2022.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。